Alphagan P

   
Google
 
Web NewDrugInformation.com

Alphagan P


Drug - Alphagan P
The trade name of the product as shown on the labeling.

Dosage - SOLUTION/DROPS; OPHTHALMIC
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Brimonidine Tartrate
Multiple ingredients are in alphabetical order.

Strength - 0.1%
The potency of the active ingredient(s), Brimonidine Tartrate. May repeat for multiple part products.

Applicant - ALLERGAN
The firm name holding legal responsibility for Alphagan P. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 021770
The FDA assigned number to Alphagan P. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Alphagan P. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Aug 19, 2005
The date Alphagan P was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - Yes
The pioneer or innovator of Alphagan P. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Alphagan P is in. Format is RX, OTC, DISCN.

Applicant Full Name - Allergan
The full name of the firm holding legal responsibility for the new application of Alphagan P.

Alphagan P